Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
committee (the Compensation Committee ) of the Board of Directors
(the Board ) of Kubota Pharmaceutical Holdings Co., Ltd. (the
Company ) approved the 2016 non-equity incentive plan
compensation and 2017 base salaries for the Companys principal
executive officer and principal financial officer. For additional
information, please see the sections titled Compensation of
Directors and Executive Officers-Summary Compensation Table and
Compensation of Directors and Executive Officers-Executive
Employment Arrangements included in the Definitive Proxy
Statement on Schedule 14A filed by Acucela Inc. with the
Securities and Exchange Commission on September 15, 2016. to Rule
12g-3(a) under the Securities Exchange Act of 1934, as amended,
the Company is the successor issuer to Acucela Inc.
|
Name
|
Title
|
2016 Non-Equity Plan
Compensation
|
2017 Base Salary
|
||
|
Ryo Kubota
|
President and Chief Executive Officer
|
$
|
159,147
|
544,248
|
|
|
John Gebhart
|
Chief Financial Officer
|
82,897
|
347,154
|
||
bonuses under the Companys 2017 non-equity incentive plan of up
to 60% and 35%, respectively, of their base salary. Dr. Kubotas
bonus is based solely on corporate goals, while Mr. Gebharts
bonus is based 70% on corporate goals and 30% on individual
goals.
About Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596)
Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome. Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) Recent Trading Information
Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) closed its last trading session down -7.00 at 914.00 with 95,900 shares trading hands.
